Reply to: Comments on "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis"

Int J Cancer. 2023 Jul 1;153(1):240-242. doi: 10.1002/ijc.34497. Epub 2023 Mar 21.

Authors

Tianqi Gu¹, Anqi Lin¹, Haitao Wang², Jian Zhang¹, Peng Luo¹

Affiliations

¹ Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
² Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

PMID: 36891965
DOI: 10.1002/ijc.34497

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Agents, Immunological* / adverse effects
Bevacizumab / adverse effects
Drug-Related Side Effects and Adverse Reactions* / epidemiology
Humans
Immune Checkpoint Inhibitors
Pharmacovigilance
Retrospective Studies

Substances

Bevacizumab
Immune Checkpoint Inhibitors
Antineoplastic Agents, Immunological
Antibodies, Monoclonal, Humanized